Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03837509 · ClinicalTrials.gov registry record · Phase 1
INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma
A Phase 1 study, sponsored by Incyte Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT03837509 is a Phase 1 study that was terminated before completion, run by Incyte Corporation. The registered enrollment target is 15 participants.
The verdict
NCT03837509, a Phase 1 study, was terminated before completion, sponsored by Incyte Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and antitumor activity of INCB001158 in combination with daratumumab SC, compared with daratumumab SC alone, in participants with relapsed or refractory multiple myeloma.
Interventions
- DRUG INCB001158
- BIOLOGICAL Daratumumab SC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2019-09-25 |
| Est. Completion | 2022-04-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03837509
The ClinicalTrials.gov registry entry for NCT03837509 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which INCB001158 is the first listed.
NCT03837509 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03837509 about?
NCT03837509 is a clinical study titled "INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma". The purpose of this study is to evaluate the safety and antitumor activity of INCB001158 in combination with daratumumab SC, compared with daratumumab SC alone, in participants with relapsed or refractory multiple myeloma.
What is the current status of trial NCT03837509?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2019-09-25. Estimated completion is 2022-04-05.
What interventions are being tested in trial NCT03837509?
The interventions under investigation include: INCB001158 (DRUG), Daratumumab SC (BIOLOGICAL).
Who is sponsoring clinical trial NCT03837509?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.